Other News To Note

• Deciphera Pharmaceuticals LLC, of Lawrence, Kan., said it plans to transition from an oncology discovery company to an oncology drug development company and will focus its resources on the continued development of rebastinib and DCC-2701, two drugs discovered using its switch pocket kinase inhibitor technology.